Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Rational Combinations of Polymyxins with Other Antibiotics.

Bergen PJ, Smith NM, Bedard TB, Bulman ZP, Cha R, Tsuji BT.

Adv Exp Med Biol. 2019;1145:251-288. doi: 10.1007/978-3-030-16373-0_16. Review.

PMID:
31364082
2.

Inoculum effect of β-lactam antibiotics.

Lenhard JR, Bulman ZP.

J Antimicrob Chemother. 2019 Oct 1;74(10):2825-2843. doi: 10.1093/jac/dkz226.

PMID:
31170287
3.

Shifting Gears: The Future of Polymyxin Antibiotics.

Lenhard JR, Bulman ZP, Tsuji BT, Kaye KS.

Antibiotics (Basel). 2019 Apr 12;8(2). pii: E42. doi: 10.3390/antibiotics8020042. Review.

4.

Successful cure of daptomycin-non-susceptible, vancomycin-intermediate Staphylococcus aureus prosthetic aortic valve endocarditis directed by synergistic in vitro time-kill study.

Sumon ZE, Berenson CS, Sellick JA, Bulman ZP, Tsuji BT, Mergenhagen KA.

Infect Dis (Lond). 2019 Apr;51(4):287-292. doi: 10.1080/23744235.2018.1533646. Epub 2019 Feb 14.

PMID:
30760062
5.

Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model.

Bulman ZP, Zhao M, Satlin MJ, Chen L, Kreiswirth BN, Walsh TJ, Nation RL, Li J, Tsuji BT.

Int J Antimicrob Agents. 2018 Jul;52(1):114-118. doi: 10.1016/j.ijantimicag.2018.02.010. Epub 2018 Feb 24.

PMID:
29486233
6.

Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and blaNDM-5: Preparation for a Postantibiotic Era.

Bulman ZP, Chen L, Walsh TJ, Satlin MJ, Qian Y, Bulitta JB, Peloquin CA, Holden PN, Nation RL, Li J, Kreiswirth BN, Tsuji BT.

MBio. 2017 Jul 25;8(4). pii: e00540-17. doi: 10.1128/mBio.00540-17.

7.

Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli.

Smith NM, Bulman ZP, Sieron AO, Bulitta JB, Holden PN, Nation RL, Li J, Wright GD, Tsuji BT.

J Antimicrob Chemother. 2017 Aug 1;72(8):2297-2303. doi: 10.1093/jac/dkx121.

8.

Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.

Zhao M, Bulman ZP, Lenhard JR, Satlin MJ, Kreiswirth BN, Walsh TJ, Marrocco A, Bergen PJ, Nation RL, Li J, Zhang J, Tsuji BT.

J Antimicrob Chemother. 2017 Jul 1;72(7):1985-1990. doi: 10.1093/jac/dkx070.

9.

New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae.

Bulman ZP, Satlin MJ, Chen L, Kreiswirth BN, Shin BS, Walsh TJ, Holden PN, Forrest A, Nation RL, Li J, Tsuji BT.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02023-16. doi: 10.1128/AAC.02023-16. Print 2017 Apr.

10.

A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA).

Shafiq I, Bulman ZP, Spitznogle SL, Osorio JE, Reilly IS, Lesse AJ, Parameswaran GI, Mergenhagen KA, Tsuji BT.

Infect Dis (Lond). 2017 May;49(5):410-416. doi: 10.1080/23744235.2016.1277587. Epub 2017 Jan 24.

PMID:
28116950
11.

Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.

Bulman ZP, Ly NS, Lenhard JR, Holden PN, Bulitta JB, Tsuji BT.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e00096-16. doi: 10.1128/AAC.00096-16. Print 2017 Apr.

12.

High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model.

Lenhard JR, Smith NM, Bulman ZP, Tao X, Thamlikitkul V, Shin BS, Nation RL, Li J, Bulitta JB, Tsuji BT.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01268-16. doi: 10.1128/AAC.01268-16. Print 2017 Mar.

13.

In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.

Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.

Int J Antimicrob Agents. 2017 Jan;49(1):25-30. doi: 10.1016/j.ijantimicag.2016.07.015. Epub 2016 Sep 1.

PMID:
27931793
14.

Native valve Proteus mirabilis endocarditis: successful treatment of a rare entity formulated by in vitro synergy antibiotic testing.

Brotzki CR, Mergenhagen KA, Bulman ZP, Tsuji BT, Berenson CS.

BMJ Case Rep. 2016 Oct 20;2016. pii: bcr2016215956. doi: 10.1136/bcr-2016-215956.

15.

Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa.

Ly NS, Bulman ZP, Bulitta JB, Baron C, Rao GG, Holden PN, Li J, Sutton MD, Tsuji BT.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2870-80. doi: 10.1128/AAC.02377-15. Print 2016 May.

16.

Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.

Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):1967-73. doi: 10.1128/AAC.02635-15. Print 2016 Apr.

17.

Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.

Lenhard JR, Brown T, Rybak MJ, Meaney CJ, Norgard NB, Bulman ZP, Brazeau DA, Gill SR, Tsuji BT.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1584-91. doi: 10.1128/AAC.02657-15.

18.

Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria.

Bergen PJ, Bulman ZP, Landersdorfer CB, Smith N, Lenhard JR, Bulitta JB, Nation RL, Li J, Tsuji BT.

Infect Dis Ther. 2015 Dec;4(4):391-415. doi: 10.1007/s40121-015-0093-7. Epub 2015 Dec 8.

19.

Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutators.

Bulman ZP, Sutton MD, Ly NS, Bulitta JB, Holden PN, Nation RL, Li J, Tsuji BT.

Antimicrob Agents Chemother. 2015 Jul;59(7):4343-6. doi: 10.1128/AAC.04629-14. Epub 2015 Apr 27.

20.

Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.

Bergen PJ, Bulman ZP, Saju S, Bulitta JB, Landersdorfer C, Forrest A, Li J, Nation RL, Tsuji BT.

Pharmacotherapy. 2015 Jan;35(1):34-42. doi: 10.1002/phar.1537. Review.

21.

Evolution of Staphylococcus aureus under vancomycin selective pressure: the role of the small-colony variant phenotype.

Lenhard JR, von Eiff C, Hong IS, Holden PN, Bear MD, Suen A, Bulman ZP, Tsuji BT.

Antimicrob Agents Chemother. 2015 Feb;59(2):1347-51. doi: 10.1128/AAC.04508-14. Epub 2014 Dec 1.

22.

A novel property of propolis (bee glue): anti-pathogenic activity by inhibition of N-acyl-homoserine lactone mediated signaling in bacteria.

Bulman Z, Le P, Hudson AO, Savka MA.

J Ethnopharmacol. 2011 Dec 8;138(3):788-97. doi: 10.1016/j.jep.2011.10.029. Epub 2011 Oct 28.

PMID:
22063726

Supplemental Content

Loading ...
Support Center